Oral Mucositis Market

DelveInsight’s Oral Mucositis Market Insights Report offers a detailed analysis of the disease, its causes, symptoms, diagnostics modalities, and treatment options. 

The Oral Mucositis market report also offers comprehensive insights into Oral Mucositis market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing Oral Mucositis market size growth forward. 

Some of the key highlights from the Oral Mucositis Market Insights Report: 

• In the year 2020, the total Oral Mucositis incident cases were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018–2030. 
• As per the DelveInsight estimates, in the United States, the total Grade-specific Oral Mucositis incident cases were highest for Grade III, with 209,660 patients in the year 2020. These cases are expected to grow in the study period 2018–2030. 
• In Germany, the total treated cases of Oral Mucositis were 116,300 in the year 2020. These cases are expected to grow in the study period 2018–2030. 
• Major players such as Galera Therapeutics, Soligenix, Monopar Therapeutics, NeoMedLight, BrainCool, MuReva (Lumitex), Oncozenge, and others are involved in developing therapies for the treatment and management of Oral Mucositis. These therapies are currently under different stages of development. 
• Key pipeline therapies in the Oral Mucositis market include Avasopasem (GC4419), SGX942, Validive (Clonidine Lauriad), CareMin650, Cooral/CoolPrevent, MuReva Phototherapy System, BupiZenge, among others.

Learn more by requesting for sample @ Oral Mucositis Market Landscape 

Oral Mucositis: Overview 

Oral mucositis refers to erythematous and ulcerative lesions of the oral mucosa observed in patients with cancer being treated with chemotherapy and with radiation therapy to fields involving the oral cavity. This can lead to several problems, including pain, nutritional problems resulting from the inability to eat, and an increased risk of infection due to open sores in the mucosa. It significantly affects the patient’s quality of life and can be dose-limiting. This condition generally begins 5-10 days following chemotherapy and lasts one week to six weeks. 

For more insights into disease, causes, and treatment, contact Oral Mucositis Treatment Landscape. 

Oral Mucositis Epidemiology Segmentation 

The Oral Mucositis Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

• Oral Mucositis Prevalence 
• Age-Specific Oral Mucositis Prevalence 
• Gender-Specific Oral Mucositis Prevalence 
• Diagnosed and Treatable Cases of Oral Mucositis 

Visit for more @ Oral Mucositis Epidemiological Insights

Oral Mucositis Market 

Oral mucositis has traditionally been treated with palliative care, while focused treatment strategies are currently being developed. Although it is impossible to prevent mucositis from developing, some steps can be taken before starting radiation.

Patients’ compliance and education, hydration, nutritional support, saline rinses, topical and systemic pain medication, and infection surveillance and treatment were all part of the traditional management of oral mucositis.

Palliative therapies such as palifermin and benzydamine have also been utilized in rare circumstances. Oral mucositis caused by cancer treatments is widely recognized as chemotherapy and radiation therapy’s most debilitating side effect.

Oral Mucositis Pipeline Therapies and Key Companies 

• Avasopasem (GC4419): Galera Therapeutics
• SGX942: Soligenix
• Validive (Clonidine Lauriad): Monopar Therapeutics
• CareMin650: NeoMedLight
• Cooral/CoolPrevent: BrainCool
• MuReva Phototherapy System: MuReva (Lumitex)
• BupiZenge: Oncozenge

For more information, visit Oral Mucositis Market Analysis, Patient Pool, and Emerging Therapies. 

Oral Mucositis Market Drivers 

• Rising prevalent population
• Technological advancements
• Emerging therapies 
• Extensive R&D

Scope of the Report

• 7MM Coverage 
• Descriptive overview of Oral Mucositis, covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight into Oral Mucositis epidemiology and treatment in the 7MM
• Current and emerging therapies for Oral Mucositis 
• Oral Mucositis market drivers and barriers 

Table of Contents 

Related Reports:

Oral Mucositis Market

Oral Mucositis Epidemiology

Oral Mucositis Pipeline

Latest Reports:

Intrahepatic Cholangiocarcinoma (ICCA) Market

COVID 19 Therapeutic Pipeline, Vaccines, and Diagnostics Competitive Landscape, 2020

Cervical Dysplasia Market

Agoraphobia Market

Hydrocephalus Market

Sarcopenia Market

Diabetic Kidney Disease Market

Acromegaly Market

Acute Respiratory Distress Syndrome (ARDS) Market

Acute Kidney Injury (AKI) Market

Renal Anemia Market

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance.  

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/